• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质-多糖HIP复合物在聚合物纳米颗粒中的包封

Encapsulation of Protein-Polysaccharide HIP Complex in Polymeric Nanoparticles.

作者信息

Gaudana Ripal, Khurana Varun, Parenky Ashwin, Mitra Ashim K

机构信息

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA.

出版信息

J Drug Deliv. 2011;2011:458128. doi: 10.1155/2011/458128. Epub 2011 Apr 27.

DOI:10.1155/2011/458128
PMID:21603214
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3095424/
Abstract

The objective of the present study is to formulate and characterize a nanoparticulate-based formulation of a macromolecule in a hydrophobic ion pairing (HIP) complex form. So far, HIP complexation approach has been studied only for proteins with molecular weight of 10-20 kDa. Hence, we have selected bovine serum albumin (BSA) having higher molecular weight (66.3 kDa) as a model protein and dextran sulphate (DS) as a complexing polymer to generate HIP complex. We have prepared and optimized the HIP complex formation process of BSA with DS. Ionic interactions between basic amino acids of BSA with sulphate groups of DS were confirmed by FTIR analysis. Further, nanoparticles were prepared and characterized with respect to size and surface morphology. We observed significant entrapment of BSA in nanoparticles prepared with minimal amounts of PLGA polymer. Finally, results of circular dichroism and intrinsic fluorescence assay have clearly indicated that HIP complexation and method of nanoparticle preparation did not alter the secondary and tertiary structures of BSA.

摘要

本研究的目的是制备并表征一种以疏水离子对(HIP)复合物形式存在的基于纳米颗粒的大分子制剂。到目前为止,HIP复合方法仅针对分子量为10 - 20 kDa的蛋白质进行了研究。因此,我们选择了分子量较高(66.3 kDa)的牛血清白蛋白(BSA)作为模型蛋白,并选择硫酸葡聚糖(DS)作为复合聚合物来生成HIP复合物。我们制备并优化了BSA与DS形成HIP复合物的过程。通过傅里叶变换红外光谱(FTIR)分析证实了BSA的碱性氨基酸与DS的硫酸基团之间的离子相互作用。此外,制备了纳米颗粒并对其尺寸和表面形态进行了表征。我们观察到,在使用最少量聚乳酸-羟基乙酸共聚物(PLGA)聚合物制备的纳米颗粒中,BSA有显著包封。最后,圆二色性和内源荧光测定结果清楚地表明,HIP复合以及纳米颗粒制备方法并未改变BSA的二级和三级结构。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/da34b3a8362d/JDD2011-458128.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/423b3aabf88a/JDD2011-458128.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/c40a7eb5a229/JDD2011-458128.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/f271fb88ddad/JDD2011-458128.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/abb4f293e8d6/JDD2011-458128.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/7e3d795f044c/JDD2011-458128.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/3891d2eec5e5/JDD2011-458128.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/da34b3a8362d/JDD2011-458128.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/423b3aabf88a/JDD2011-458128.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/c40a7eb5a229/JDD2011-458128.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/f271fb88ddad/JDD2011-458128.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/abb4f293e8d6/JDD2011-458128.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/7e3d795f044c/JDD2011-458128.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/3891d2eec5e5/JDD2011-458128.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ea/3095424/da34b3a8362d/JDD2011-458128.007.jpg

相似文献

1
Encapsulation of Protein-Polysaccharide HIP Complex in Polymeric Nanoparticles.蛋白质-多糖HIP复合物在聚合物纳米颗粒中的包封
J Drug Deliv. 2011;2011:458128. doi: 10.1155/2011/458128. Epub 2011 Apr 27.
2
Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme.设计并评估了一种新型的基于纳米颗粒的制剂,该制剂包封了溶菌酶的 HIP 复合物。
Pharm Dev Technol. 2013 May-Jun;18(3):752-9. doi: 10.3109/10837450.2012.737806. Epub 2012 Nov 9.
3
Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation.通过 HIP 络合技术制备水溶解度前药地塞米松的纳米粒制剂的开发和特性研究。
J Microencapsul. 2011;28(1):10-20. doi: 10.3109/02652048.2010.520093. Epub 2010 Oct 12.
4
A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation.一种通过疏水离子对络合作用开发抗体纳米载体的新方法。
J Microencapsul. 2014;31(6):542-50. doi: 10.3109/02652048.2014.885606. Epub 2014 Apr 3.
5
Effect of chitosan salts and molecular weight on a nanoparticulate carrier for therapeutic protein.壳聚糖盐和分子量对治疗性蛋白质纳米颗粒载体的影响。
Pharm Dev Technol. 2005;10(2):189-96. doi: 10.1081/pdt-54388.
6
Stability of bovine serum albumin complexed with PEG-poly(L-histidine) diblock copolymer in PLGA microspheres.聚乳酸-羟基乙酸共聚物微球中与聚乙二醇-聚(L-组氨酸)二嵌段共聚物复合的牛血清白蛋白的稳定性
J Control Release. 2005 Dec 5;109(1-3):86-100. doi: 10.1016/j.jconrel.2005.09.016. Epub 2005 Nov 2.
7
Contrasting effect of gold nanoparticles and nanorods with different surface modifications on the structure and activity of bovine serum albumin.不同表面修饰的金纳米粒子和纳米棒对牛血清白蛋白结构和活性的对比影响。
Langmuir. 2011 Jun 21;27(12):7722-31. doi: 10.1021/la200787t. Epub 2011 May 17.
8
Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method.固体/油/水离子对法制备载米诺环素 PLGA 纳米粒及其载药量和抗菌活性的改善。
Int J Nanomedicine. 2012;7:221-34. doi: 10.2147/IJN.S27709. Epub 2012 Jan 10.
9
Designing chitosan-dextran sulfate nanoparticles using charge ratios.利用电荷比设计壳聚糖-硫酸葡聚糖纳米颗粒。
AAPS PharmSciTech. 2007 Nov 30;8(4):E98. doi: 10.1208/pt0804098.
10
Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation.通过聚电解质络合制备的肝素/壳聚糖纳米颗粒载体。
J Biomed Mater Res A. 2007 Dec 1;83(3):806-12. doi: 10.1002/jbm.a.31407.

引用本文的文献

1
Challenges and Complications of Poly(lactic--glycolic acid)-Based Long-Acting Drug Product Development.聚(乳酸-乙醇酸)基长效药物产品开发的挑战与并发症
Pharmaceutics. 2022 Mar 11;14(3):614. doi: 10.3390/pharmaceutics14030614.
2
Formulation and Efficacy of Catalase-Loaded Nanoparticles for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy.用于治疗新生儿缺氧缺血性脑病的载过氧化氢酶纳米颗粒的制剂与疗效
Pharmaceutics. 2021 Jul 23;13(8):1131. doi: 10.3390/pharmaceutics13081131.
3
Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers.

本文引用的文献

1
Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation.通过 HIP 络合技术制备水溶解度前药地塞米松的纳米粒制剂的开发和特性研究。
J Microencapsul. 2011;28(1):10-20. doi: 10.3109/02652048.2010.520093. Epub 2010 Oct 12.
2
Stability of protein pharmaceuticals: an update.蛋白质类药物的稳定性:最新进展。
Pharm Res. 2010 Apr;27(4):544-75. doi: 10.1007/s11095-009-0045-6. Epub 2010 Feb 9.
3
Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation.
疏水离子对:将小分子、肽和蛋白质封装到纳米载体中。
Nanoscale Adv. 2019 Oct 1;1(11):4207-4237. doi: 10.1039/c9na00308h.
4
Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles.可逆疏水离子对复合物策略,以最大限度减少奥曲肽从聚乳酸-羟基乙酸共聚物(PLGA)微粒长期释放过程中的酰化反应。
Int J Pharm. 2015 Jul 15;489(1-2):237-45. doi: 10.1016/j.ijpharm.2015.04.075. Epub 2015 May 1.
5
Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand.使用糖配体实现磷酸伯氨喹纳米碳复合物的受体介导的肝细胞靶向递送。
Drug Deliv Transl Res. 2014 Aug;4(4):353-64. doi: 10.1007/s13346-014-0200-4.
6
Long-term delivery of protein therapeutics.蛋白质治疗药物的长期递送。
Expert Opin Drug Deliv. 2015 Mar;12(3):415-40. doi: 10.1517/17425247.2015.961420. Epub 2014 Sep 24.
7
Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles.蛋白质和肽类药物递送的最新进展:特别关注聚合物纳米颗粒
Protein Pept Lett. 2014;21(11):1102-20. doi: 10.2174/0929866521666140807114240.
8
A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation.一种通过疏水离子对络合作用开发抗体纳米载体的新方法。
J Microencapsul. 2014;31(6):542-50. doi: 10.3109/02652048.2014.885606. Epub 2014 Apr 3.
9
Recent developments in protein and peptide parenteral delivery approaches.蛋白质和肽类肠胃外给药方法的最新进展。
Ther Deliv. 2014 Mar;5(3):337-65. doi: 10.4155/tde.14.5.
10
Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme.设计并评估了一种新型的基于纳米颗粒的制剂,该制剂包封了溶菌酶的 HIP 复合物。
Pharm Dev Technol. 2013 May-Jun;18(3):752-9. doi: 10.3109/10837450.2012.737806. Epub 2012 Nov 9.
载胰岛素-S.O(油酸钠)复合物的 PLGA 纳米粒:制剂、表征及体内评价。
J Microencapsul. 2010;27(6):471-8. doi: 10.3109/02652040903515490.
4
Delivery of therapeutic proteins.治疗性蛋白的递送。
J Pharm Sci. 2010 Jun;99(6):2557-75. doi: 10.1002/jps.22054.
5
Formulating protein therapeutics into particulate forms.将蛋白质治疗剂制成颗粒形式。
Expert Opin Drug Deliv. 2009 Oct;6(10):1123-33. doi: 10.1517/17425240903156374.
6
Sustained and extended release with structural and activity recovery of lysozyme from complexes with sodium (sulfamate carboxylate) isoprene/ethylene oxide block copolymer.从与磺酸盐羧酸酯基异戊二烯/环氧乙烷嵌段共聚物形成的复合物中,溶菌酶具有结构和活性的恢复,实现持续和延长的释放。
Macromol Biosci. 2010 Feb 11;10(2):139-46. doi: 10.1002/mabi.200900186.
7
Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin.基于壳聚糖-硫酸软骨素的基质片剂用于吲哚美辛的结肠特异性递送。
AAPS PharmSciTech. 2009;10(2):670-7. doi: 10.1208/s12249-009-9253-y. Epub 2009 May 21.
8
Design of high payload PLGA nanoparticles containing melittin/sodium dodecyl sulfate complex by the hydrophobic ion-pairing technique.采用疏水离子对技术设计高载药量的含蜂毒素/十二烷基硫酸钠复合物的 PLGA 纳米粒。
Drug Dev Ind Pharm. 2009 Aug;35(8):959-68. doi: 10.1080/03639040902718039.
9
Current approaches to stabilising and analysing proteins during microencapsulation in PLGA.聚乳酸-羟基乙酸共聚物(PLGA)微囊化过程中蛋白质稳定化及分析的当前方法。
Expert Opin Drug Deliv. 2009 Feb;6(2):177-86. doi: 10.1517/17425240802680169.
10
Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles.通过脂质纳米颗粒改善亲水性肽药物包封的策略。
Colloids Surf B Biointerfaces. 2009 May 1;70(2):248-53. doi: 10.1016/j.colsurfb.2008.12.031. Epub 2008 Dec 31.